

From: [REDACTED] (GROW)
To: [REDACTED] (GROW)
Subject: FW: final Document of Cannabis
Date: mercredi 6 mars 2019 16:48:59
Attachments: [image001.png](#)
[image002.jpg](#)
[image003.png](#)
[image004.png](#)

ARES please



From: [REDACTED] (GROW)
Sent: Wednesday, March 6, 2019 4:48 PM
To: [REDACTED]
Subject: RE: final Document of Cannabis

Dear [REDACTED],

In the last WG meeting, different stakeholders considered that the Single Convention on Narcotic Drugs is not up-to-date. In response to this, the commission services acknowledged the issue, but remarked that in order to mandate SCCS, safety data must be provided.

Kind regards

[REDACTED]

From: [REDACTED] <[REDACTED]@sozialministerium.at>
Sent: Wednesday, March 6, 2019 3:33 PM
To: [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>

Subject: AW: final Document of Cannabis

Dear [REDACTED], many thanks for clarification. This does not affect the safety of CBD as a cosmetic raw material. During the meeting, the KOM has made a proposal for transmitting Datas of CBD to give a mandate to SCCS.

Is this proposal still valid?

Thanks a lot

Best regards

Von: [REDACTED] <[REDACTED]@ec.europa.eu [mailto:[REDACTED]]>
[REDACTED] <[REDACTED]@ec.europa.eu>

Gesendet: Montag, 4. März 2019 18:27

An: [REDACTED]

Cc: [REDACTED] <[REDACTED]@ec.europa.eu>

Betreff: RE: final Document of Cannabis

Dear Dr. [REDACTED],

Based on the discussions held in the Working Group meeting in February 2019 and the recent document shared via CIRCABC, we consider that the cannabis leaves are exempted from the definition of Cannabis according to the Single Convention on Narcotics. Therefore, with the current legal basis, if CBD is prepared from cannabis leaves it is not prohibited.

For clarity reasons in CosIng, we will probably introduce the entry "CANNABIDIOL, derived from extract or tincture or resin of Cannabis" instead of "CANNABIDIOL, plant-derived".

We hope you find this information helpful.

Kind regards,

[REDACTED]



European Commission

DG for Internal Market, Industry, Entrepreneurship and SMEs

Unit D4 – Health Technology and Cosmetics
BREY [REDACTED]
B-1049 Brussels/Belgium
Phone: [REDACTED]
E-mail: [REDACTED]@ec.europa.eu
Website: [Cosmetics & Medical Devices](#)
Follow us on
Facebook: [EU Growth](#)
Twitter: [@EU_Growth](#)
Our Websites: [ec.europa.eu/growth](#)
[ec.europa.eu/bienkowska](#)

From: [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>

Sent: Monday, March 4, 2019 2:48 PM

To: [REDACTED] <[REDACTED]@sozialministerium.at>

Cc: [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>

Subject: RE: final Document of Cannabis

Dear [REDACTED],

Thank you for your email.

My colleague [REDACTED], in charge of the scientific aspects of this file, will reply to you in due course.

Thanks in advance!

Kind regards,

[REDACTED]

From: [REDACTED] <[REDACTED]@sozialministerium.at>

Sent: Thursday, February 28, 2019 1:12 PM

To: [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>

Subject: final Document of Cannabis

Dear [REDACTED],

During the meeting a revised document was presented concerning the list of authorised and prohibited products of cannabis. Could you please tell me when this document will be placed on Circabc?

One question I have please what 's your view on this?

Are extracts from the leaves of Cannabis Sativa - and consequently CBD made from them - subject to Prohibition Entry 306 of Regulation (EC) No 1223/2009 ?

Best regards

[REDACTED]



BUNDESMINISTERIUM FÜR
ARBEIT, SOZIALES, GESUNDHEIT
UND KONSUMENTENSCHUTZ

Dr. in [REDACTED]

Leiterin der Abteilung IX/B/14

Veterinärmedizin und Veterinärwesen, Lebensmittelsicherheit:

Stoffliche und technologische Risiken,

Gentechnik

Radetzkystraße 2, 1030 Wien

Tel: [REDACTED]

[REDACTED]@sozialministerium.at



sozialministerium.at

facebook.com/sozialministerium

